{"url_path":"/sec/mplt/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224067-index.html","accession_number":"0001193125-26-224067","cik":"0001770069","ticker":"MPLT","issuer_name":"MapLight Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224067-index.html","primary_entity_key":"0001770069","primary_entity_name":"MapLight Therapeutics, Inc."},"word_count":159,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\n## On May 14, 2026, MapLight Therapeutics, Inc. (the \"Company\") issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\n## In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed \"filed\" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended (the \"Securities Act\"), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing."}